FDA is expected to make a decision on two genetic therapies for sickle cell disease later this year, both of which the Institute of Clinical and Economic Review’s (ICER) independent appraisers say would provide patients benefits beyond what is currently available from other treatments. But the appraisers say the ultimate cost-effectiveness of the products depends on what the companies decide to charge if they get FDA approval. ICER’s California Technology Assessment Forum (CTAF), the organization’s independent appraisal committee, met July...